Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31


Gene therapy with apoptosis-associated speck-like protein (ASC), a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo.

Ahmed SG, Ahmed A, Maguire CA, Doha M, Sagers J, Lewis RM, Muzikansky A, Giovannini M, Stemmer-Rachamimov A, Stankovic KM, Fulci G, Brenner GJ.

Neuro Oncol. 2019 Apr 12. pii: noz065. doi: 10.1093/neuonc/noz065. [Epub ahead of print]


Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles.

Zaborowski MP, Lee K, Na YJ, Sammarco A, Zhang X, Iwanicki M, Cheah PS, Lin HY, Zinter M, Chou CY, Fulci G, Tannous BA, Lai CP, Birrer MJ, Weissleder R, Lee H, Breakefield XO.

Cell Rep. 2019 Apr 2;27(1):255-268.e6. doi: 10.1016/j.celrep.2019.03.003.


Direct saturation-corrected chemical exchange saturation transfer MRI of glioma: Simplified decoupling of amide proton transfer and nuclear overhauser effect contrasts.

Yuwen Zhou I, Wang E, Cheung JS, Lu D, Ji Y, Zhang X, Fulci G, Sun PZ.

Magn Reson Med. 2017 Dec;78(6):2307-2314. doi: 10.1002/mrm.26959. Epub 2017 Oct 13.


Quantitative chemical exchange saturation transfer (CEST) MRI of glioma using Image Downsampling Expedited Adaptive Least-squares (IDEAL) fitting.

Zhou IY, Wang E, Cheung JS, Zhang X, Fulci G, Sun PZ.

Sci Rep. 2017 Mar 7;7(1):84. doi: 10.1038/s41598-017-00167-y.


Surface biotinylation of cytotoxic T lymphocytes for in vivo tracking of tumor immunotherapy in murine models.

Li A, Wu Y, Linnoila J, Pulli B, Wang C, Zeller M, Ali M, Lewandrowski GK, Li J, Tricot B, Keliher E, Wojtkiewicz GR, Fulci G, Feng X, Tannous BA, Yao Z, Chen JW.

Cancer Immunol Immunother. 2016 Dec;65(12):1545-1554. Epub 2016 Oct 8.


Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models.

Ye H, Tanenbaum LM, Na YJ, Mantzavinou A, Fulci G, Del Carmen MG, Birrer MJ, Cima MJ.

J Control Release. 2015 Dec 28;220(Pt A):358-367. doi: 10.1016/j.jconrel.2015.11.001. Epub 2015 Nov 5.


The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity.

Kleijn A, Kloezeman J, Treffers-Westerlaken E, Fulci G, Leenstra S, Dirven C, Debets R, Lamfers M.

Oncoimmunology. 2014 Dec 13;3(9):e955697. eCollection 2014 Oct.


Establishing the Lysine-rich Protein CEST Reporter Gene as a CEST MR Imaging Detector for Oncolytic Virotherapy.

Farrar CT, Buhrman JS, Liu G, Kleijn A, Lamfers ML, McMahon MT, Gilad AA, Fulci G.

Radiology. 2015 Jun;275(3):746-54. doi: 10.1148/radiol.14140251. Epub 2015 Feb 13.


The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.

Kleijn A, Kloezeman J, Treffers-Westerlaken E, Fulci G, Leenstra S, Dirven C, Debets R, Lamfers M.

PLoS One. 2014 May 27;9(5):e97495. doi: 10.1371/journal.pone.0097495. eCollection 2014.


Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.

Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL.

Neoplasia. 2013 Jun;15(6):591-9.


Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1.

Prabhakar S, Taherian M, Gianni D, Conlon TJ, Fulci G, Brockmann J, Stemmer-Rachamimov A, Sena-Esteves M, Breakefield XO, Brenner GJ.

Hum Gene Ther. 2013 Feb;24(2):152-62. doi: 10.1089/hum.2012.094. Epub 2013 Jan 30.


Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.

Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR, Weissleder R, Rabkin SD, Martuza RL.

Mol Ther. 2012 Jan;20(1):37-45. doi: 10.1038/mt.2011.187. Epub 2011 Sep 13.


Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging.

Kleijn A, Chen JW, Buhrman JS, Wojtkiewicz GR, Iwamoto Y, Lamfers ML, Stemmer-Rachamimov AO, Rabkin SD, Weissleder R, Martuza RL, Fulci G.

Clin Cancer Res. 2011 Jul 1;17(13):4484-93. doi: 10.1158/1078-0432.CCR-11-0575. Epub 2011 May 10.


Analysis of HSV oncolytic virotherapy in organotypic cultures.

Fulci G, Passer B.

Methods Mol Biol. 2009;542:75-86. doi: 10.1007/978-1-59745-561-9_3.


Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy.

Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder R, Carson W, Chiocca EA, Kaur B.

J Natl Cancer Inst. 2007 Dec 5;99(23):1768-81. Epub 2007 Nov 27.


Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses.

Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y, Kaufman CS, Kaur B, Lawler SE, Lee RJ, Marsh CB, Brat DJ, van Rooijen N, Stemmer-Rachamimov AO, Hochberg FH, Weissleder R, Martuza RL, Chiocca EA.

Cancer Res. 2007 Oct 1;67(19):9398-406. Erratum in: Cancer Res. 2007 Nov 15;67(22):11092. Rachamimov, Anat Stemmer [corrected to Stemmer-Rachamimov, Anat O].


The status of gene therapy for brain tumors.

Fulci G, Chiocca EA.

Expert Opin Biol Ther. 2007 Feb;7(2):197-208. Review.


Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.

Lamfers ML, Fulci G, Gianni D, Tang Y, Kurozumi K, Kaur B, Moeniralm S, Saeki Y, Carette JE, Weissleder R, Vandertop WP, van Beusechem VW, Dirven CM, Chiocca EA.

Mol Ther. 2006 Dec;14(6):779-88. Epub 2006 Sep 22.


Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.

Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, Kaur B, Louis DN, Weissleder R, Caligiuri MA, Chiocca EA.

Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12873-8. Epub 2006 Aug 14.


Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity.

Friedman A, Tian JP, Fulci G, Chiocca EA, Wang J.

Cancer Res. 2006 Feb 15;66(4):2314-9.


Replicative oncolytic herpes simplex viruses in combination cancer therapies.

Post DE, Fulci G, Chiocca EA, Van Meir EG.

Curr Gene Ther. 2004 Mar;4(1):41-51. Review.


Viral therapy for glioblastoma.

Chiocca EA, Aghi M, Fulci G.

Cancer J. 2003 May-Jun;9(3):167-79. Review.


Oncolytic viruses for the therapy of brain tumors and other solid malignancies: a review.

Fulci G, Chiocca EA.

Front Biosci. 2003 May 1;8:e346-60. Review.


Restoration of endogenous wild-type p53 activity in a glioblastoma cell line with intrinsic temperature-sensitive p53 induces growth arrest but not apoptosis.

Ikeda J, Tada M, Ishii N, Saya H, Tsuchiya K, Okaichi K, Mishima K, Sawamura Y, Fulci G, Liu TJ, Van Meir EG.

Int J Cancer. 2001 Oct 1;94(1):35-43.


p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma.

Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG.

Oncogene. 2000 Aug 3;19(33):3816-22.


Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells.

Tenan M, Fulci G, Albertoni M, Diserens AC, Hamou MF, El Atifi-Borel M, Feige JJ, Pepper MS, Van Meir EG.

J Exp Med. 2000 May 15;191(10):1789-98.


p53 and the CNS: tumors and developmental abnormalities.

Fulci G, Van Meir EG.

Mol Neurobiol. 1999 Feb;19(1):61-77. Review.


p53 and brain tumors: from gene mutations to gene therapy.

Fulci G, Ishii N, Van Meir EG.

Brain Pathol. 1998 Oct;8(4):599-613. Review.


Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha.

Moro M, Pelagi M, Fulci G, Paganelli G, Dellabona P, Casorati G, Siccardi AG, Corti A.

Cancer Res. 1997 May 15;57(10):1922-8.

Supplemental Content

Support Center